Review article: Controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 3, 2014, Pages 282-301

  Karlsen, T H ^a,b   Vesterhus, M ^a,c   Boberg, K M ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2 OCTYNOIC ACID; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AUTOANTIGEN; AZATHIOPRINE; BEZAFIBRATE; BILIRUBIN; BIOLOGICAL MARKER; BUDESONIDE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; GLUTEN; INFLIXIMAB; INTERLEUKIN 23; LAMIVUDINE; METHOTREXATE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PREGNANE X RECEPTOR; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; USTEKINUMAB; ZIDOVUDINE;

ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CHOLESTATIC LIVER CIRRHOSIS; CLINICAL PRACTICE; CLINICAL RESEARCH; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ELASTOGRAPHY; ENDOSCOPIC SURGERY; ENVIRONMENTAL FACTOR; FATIGUE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDICAL CARE; MOLECULAR BIOLOGY; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT CARE; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; PROGNOSIS; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 84891868569     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12581     Document Type: Article

References (181)

1. Trauner M, Meier PJ, Boyer JL,. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.
2. Karlsen TH, Hov JR,. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol 2010; 26: 251-8.
3. Halilbasic E, Claudel T, Trauner M,. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013; 58: 155-68.
4. Hirschfield GM, Heathcote EJ, Gershwin ME,. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-96.
5. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL,. The genetics of complex cholestatic disorders. Gastroenterology 2013; 144: 1357-74.
6. Bull LN, van Eijk MJ, Pawlikowska L, et al,. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18: 219-24.
7. Strautnieks SS, Bull LN, Knisely AS, et al,. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20: 233-8.
8. Deleuze JF, Jacquemin E, Dubuisson C, et al,. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996; 23: 904-8.
9. Smit JJ, Schinkel AH, Oude Elferink RP, et al,. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-62.
10. Mells GF, Kaser A, Karlsen TH,. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun 2013; 46: 41-54.
11. Padda MS, Sanchez M, Akhtar AJ, Boyer JL,. Drug-induced cholestasis. Hepatology 2011; 53: 1377-87.
12. Lammert F, Miquel JF,. Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008; 48 (Suppl. 1): S124-35.
13. Ling SC,. Congenital cholestatic syndromes: what happens when children grow up? Can J Gastroenterol 2007; 21: 743-51.
14. Hirschfield GM, Gershwin ME,. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8: 303-30.
15. Liu H, Norman GL, Shums Z, et al,. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010; 35: 436-42.
16. Dahnrich C, Pares A, Caballeria L, et al,. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009; 55: 978-85.
17. Bizzaro N, Covini G, Rosina F, et al,. Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol 2012; 42: 288-97.
18. Feuchtinger M, Christ S, Preuss B, et al,. Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut 2009; 58: 983-9.
19. Jin Q, Moritoki Y, Lleo A, et al,. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55: 1495-506.
20. Liu X, Invernizzi P, Lu Y, et al,. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010; 42: 658-60.
21. Hirschfield GM, Heathcote EJ,. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 2008; 12: 323-31.
22. Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R,. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment Pharmacol Ther 2003; 17: 17-27.
23. Neuberger J,. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev 2003; 2: 1-7.
24. van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, Houwen RH,. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol 2002; 36: 439-43.
25. Gotthardt D, Runz H, Keitel V, et al,. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008; 48: 1157-66.
26. Bjornsson E, Olsson R, Bergquist A, et al,. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-80.
27. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER,. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-8.
28. Pasha T, Heathcote J, Gabriel S, et al,. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999; 29: 21-6.
29. Poupon RE, Balkau B, Eschwege E, Poupon R,. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-54.
30. Pares A, Caballeria L, Rodes J,. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-20.
31. Tsochatzis EA, Gurusamy KS, Gluud C, Burroughs AK,. Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. J Hepatol. 2009; 51: 1084-5.
32. Gong Y, Huang ZB, Christensen E, Gluud C,. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008; Cd000551.
33. Goulis J, Leandro G, Burroughs AK,. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-60.
34. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF,. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-38.
35. Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS,. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther 2013; 38: 794-803.
36. Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD,. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2012; 32: 790-5.
37. Corpechot C, Abenavoli L, Rabahi N, et al,. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
38. Angulo P, Lindor KD, Therneau TM, et al,. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-21.
39. Kumagi T, Guindi M, Fischer SE, et al,. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-94.
40. Beuers U,. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-28.
41. Corpechot C,. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 1): S13-20.
42. Lens S, Leoz M, Nazal L, Bruguera M, Pares A,. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2013; doi: 10.1111/liv.12290 [Epub ahead of print].
43. Honda A, Ikegami T, Nakamuta M, et al,. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57: 1931-41.
44. Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, Schinkel AH,. PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci 2009; 36: 565-71.
45. Rabahi N, Chretien Y, Gaouar F, et al,. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010; 34: 283-7.
46. Pagan B, Erdozain JC, Comas C, Martin-Chavarri S, Lopez M, Gomez-Cerezo JF,. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage. Eur J Intern Med 2006; 17: 508-10.
47. Rautiainen H, Karkkainen P, Karvonen AL, et al,. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41: 747-52.
48. Leuschner M, Maier KP, Schlichting J, et al,. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117: 918-25.
49. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD,. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31: 318-23.
50. Liu JZ, Almarri MA, Gaffney DJ, et al,. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet 2012; 44: 1137-41.
51. Lleo A, Gershwin ME, Mantovani A, Invernizzi P,. Towards common denominators in primary biliary cirrhosis: the role of IL-12. J Hepatol 2012; 56: 731-3.
52. Hirschfield GM, Liu X, Xu C, et al,. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 Variants. N Engl J Med 2009; 360: 2544-55.
53. Nakamura M, Nishida N, Kawashima M, et al,. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012; 91: 721-8.
54. Yeilding N, Szapary P, Brodmerkel C, et al,. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives-an update. Ann N Y Acad Sci 2012; 1263: 1-12.
55. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH,. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796-804.
56. Mason AL,. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 2011; 54: 1312-4.
57. Selmi C,. The evidence does not support a viral etiology for primary biliary cirrhosis. J Hepatol 2011; 54: 1315-6.
58. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST,. Clinical Trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28: 886-94.
59. Selmi C, De Santis M, Cavaciocchi F, Gershwin ME,. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers 2010; 29: 287-99.
60. Amano K, Leung PS, Rieger R, et al,. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 2005; 174: 5874-83.
61. Sollid LM, Jabri B,. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol 2013; 13: 294-302.
62. Bachs L, Pares A, Elena M, Piera C, Rodes J,. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-80.
63. Ghent CN, Carruthers SG,. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-93.
64. Gershwin ME, Selmi C, Worman HJ, et al,. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194-202.
65. Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ,. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology 2006; 44: 1564-71.
66. Corpechot C, Gaouar F, Chretien Y, Johanet C, Chazouilleres O, Poupon R,. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012; 56: 218-24.
67. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
68. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ,. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
69. Neuberger J,. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol 2003; 39: 142-8.
70. Gross CR, Malinchoc M, Kim WR, et al,. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999; 29: 356-64.
71. Pells G, Mells GF, Carbone M, et al,. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 2013; 59: 67-73.
72. Silveira MG, Suzuki A, Lindor KD,. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008; 48: 1149-56.
73. Cavazza A, Caballeria L, Floreani A, et al,. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50: 1162-8.
74. Kuiper EM, Hansen BE, Adang RP, et al,. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010; 22: 1495-502.
75. Sherman M, Bruix J, Porayko M, Tran T,. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56: 793-6.
76. Lederle FA, Pocha C,. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012; 156: 387-9.
77. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
78. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH,. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010; 10: 720-6.
79. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al,. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13: 1236-45.
80. Guy JE, Qian P, Lowell JA, Peters MG,. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005; 11: 1252-7.
81. Carbone M, Neuberger J,. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol 2011; 35: 446-54.
82. Jacob DA, Neumann UP, Bahra M, et al,. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20: 211-20.
83. Bungay HK, Buchel OC, Cummings F, Travis SPL, Chapman RW,. Prevalence and determinants of primary sclerosing cholangitis in a cohort of patients with inflammatory bowel disease and normal liver function tests. Gut 2008; 1: A107.
84. Schrumpf E, Boberg KM,. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 553-62.
85. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB,. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13: 766-72.
86. Abarbanel DN, Seki SM, Davies Y, et al,. Immunomodulatory effect of vancomycin on treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33: 397-406.
87. Trivedi PJ, Adams DH,. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013; 46: 97-111.
88. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH,. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150-7.
89. Mendes FD, Jorgensen R, Keach J, et al,. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
90. Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM,. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012; 107: 56-63.
91. Webster GJ, Pereira SP, Chapman RW,. Autoimmune pancreatitis/IgG4- associated cholangitis and primary sclerosing cholangitis-overlapping or separate diseases? J Hepatol 2009; 51: 398-402.
92. Zhang L, Lewis JT, Abraham SC, et al,. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol 2010; 34: 88-94.
93. Ali S, Fisher SE, Meaney C, Greig PD, Therapondos G, Hirschfield GM,. High prevalence of IgG4 positive immunohistochemical cholangitis in liver explants from patients with PSC. Hepatology 2010; 1: 490A.
94. Dite P, Novotny I, Trna J, Sevcikova A,. Autoimmune pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22: 131-43.
95. Kamisawa T, Funata N, Hayashi Y, et al,. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.
96. Hamano H, Kawa S, Horiuchi A, et al,. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-8.
97. Maillette de Buy Wenniger L, Rauws EA, Beuers U,. What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree. Endoscopy 2012; 44: 66-73.
98. Ohara H, Nakazawa T, Kawa S, et al,. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol 2013; 28: 1247-51.
99. Raina A, Yadav D, Regueiro M, et al,. Mucosal IgG4 cell infiltration in ulcerative colitis is linked to disease activity and primary sclerosing cholangitis. Inflamm Bowel Dis 2013; 19: 1232-7.
100. Oseini AM, Chaiteerakij R, Shire AM, et al,. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011; 54: 940-8.
101. Bjornsson E, Chari S, Silveira M, et al,. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198-205.
102. Chapman R, Fevery J, Kalloo A, et al,. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
103. Broome U, Lindberg G, Lofberg R,. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992; 102: 1877-80.
104. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO,. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
105. Riley TR, Schoen RE, Lee RG, Rakela J,. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279-82.
106. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M,. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005; 20: 366-70.
107. Lundqvist K, Broome U,. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-6.
108. Schrumpf E, Fausa O, Elgjo K, Kolmannskog F,. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988; 8: 201-9.
109. Boberg KM, Lind GE,. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 2011; 25: 753-64.
110. Boberg KM, Bergquist A, Mitchell S, et al,. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-11.
111. Boonstra K, Weersma RK, van Erpecum KJ, et al,. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-55.
112. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD,. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-17.
113. Karlsen TH, Schrumpf E, Boberg KM,. Gallbladder polyps in primary sclerosing cholangitis: not so benign. Curr Opin Gastroenterol 2008; 24: 395-9.
114. Wannhoff A, Hov JR, Folseraas T, et al,. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2013; 59: 1278-84.
115. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP,. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001; 34: 360-5.
116. Rabinovitz M, Zajko AB, Hassanein T, et al,. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology 1990; 1: 747-52.
117. Lindor KD, Kowdley KV, Luketic VA, et al,. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
118. Eaton JE, Silveira MG, Pardi DS, et al,. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-45.
119. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A,. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40: 693-8.
120. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW,. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800.
121. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD,. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-62.
122. Chapman RW,. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 2009; 50: 671-3.
123. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW,. Improvement of serum alkaline phosphatase to & lt;1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-34.
124. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A,. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-6.
125. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD,. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011; 43: 309-13.
126. Cohen BI, Hofmann AF, Mosbach EH, et al,. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 1986; 91: 189-97.
127. Fickert P, Pollheimer MJ, Silbert D, et al,. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013; 58: 1201-8.
128. Halilbasic E, Fiorotto R, Fickert P, et al,. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009; 49: 1972-81.
129. Lindor KD,. New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011; 29: 113-6.
130. Kakiyama G, Pandak WM, Gillevet PM, et al,. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-55.
131. Nicholson JK, Holmes E, Kinross J, et al,. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-7.
132. Duboc H, Rajca S, Rainteau D, et al,. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62: 531-9.
133. Swann JR, Want EJ, Geier FM, et al,. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 2010; 108 (Suppl 1): 4523-30.
134. Nakken KE, Nygard S, Haaland T, et al,. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol 2007; 42: 1245-55.
135. Karlsen TH, Boberg KM,. Update on primary sclerosing cholangitis. J Hepatol 2013; 59: 571-82.
136. Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouilleres O, Arrive L,. Radiologic course of primary sclerosing cholangitis: assessment by 3D- magnetic resonance cholangiography and predictive features of progression. Hepatology 2013; doi: 10.1002/hep.26620 [Epub ahead of print].
137. Ponsioen CY, Reitsma JB, Boberg KM, Aabakken L, Rauws EA, Schrumpf E,. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy 2010; 42: 742-7.
138. Corpechot C, El Naggar A, Poujol-Robert A, et al,. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-24.
139. Rustemovic N, Cukovic-Cavka S, Opacic M, et al,. Endoscopic ultrasound elastography as a method for screening the patients with suspected primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2010; 22: 748-53.
140. Righi S, Fiorini E, De Molo C, et al,. ARFI elastography in patients with chronic autoimmune liver diseases: a preliminary study. J Ultrasound 2012; 15: 226-31.
141. Stiehl A, Rudolph G, Sauer P, et al,. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997; 26: 560-6.
142. van Milligen de Wit AW, Rauws EA, van Bracht J, et al,. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997; 46: 344-7.
143. Kaya M, Petersen BT, Angulo P, et al,. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1059-66.
144. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R,. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 502-8.
145. Bjoro K, Schrumpf E,. Liver transplantation for primary sclerosing cholangitis. J Hepatol 2004; 40: 570-7.
146. Bangarulingam SY, Bjornsson E, Enders F, et al,. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010; 51: 174-80.
147. Halme L, Arola J, Numminen K, Krogerus L, Makisalo H, Farkkila M,. Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int 2012; 32: 783-9.
148. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC,. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010; 34: 27-34.
149. Neuberger J, Jothimani D,. Long-term immunosuppression for prevention of nonviral disease recurrence. Transplant Proc 2005; 37: 1671-4.
150. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8.
151. Alabraba E, Nightingale P, Gunson B, et al,. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-40.
152. Fosby B, Karlsen TH, Melum E,. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15.
153. Maheshwari A, Yoo HY, Thuluvath PJ,. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004; 99: 538-42.
154. Jorgensen KK, Lindstrom L, Cvancarova M, et al,. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 517-23.
155. Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G,. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003; 18: 33-44.
156. Verdonk RC, Dijkstra G, Haagsma EB, et al,. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-9.
157. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E,. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-85.
158. Hennes EM, Zeniya M, Czaja AJ, et al,. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
159. Luth S, Kanzler S, Frenzel C, et al,. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009; 43: 75-80.
160. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA,. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-20.
161. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R,. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-6.
162. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R,. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
163. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP,. The biliary HCO(3) (-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010; 52: 1489-96.
164. Parks DJ, Blanchard SG, Bledsoe RK, et al,. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.
165. Guo GL, Lambert G, Negishi M, et al,. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 2003; 278: 45062-71.
166. Salas JT, Banales JM, Sarvide S, et al,. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008; 134: 1482-93.
167. Keitel V, Haussinger D,. TGR5 in cholangiocytes. Curr Opin Gastroenterol 2013; 29: 299-304.
168. Bergasa NV,. The itch of liver disease. Semin Cutan Med Surg 2011; 30: 93-8.
169. Kremer AE, Oude Elferink RP, Beuers U,. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 2011; 35: 89-97.
170. Beuers U, Kremer AE, Bolier R, Oude Elferink RP,. Pruritus in cholestasis-facts and fiction. Hepatology 2014; (in press).
171. Kremer AE, Martens JJ, Kulik W, et al,. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139: 1008-18.
172. Alemi F, Kwon E, Poole DP, et al,. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013; 123: 1513-30.
173. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G,. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992; 15: 603-8.
174. Quist RG, Ton-Nu HT, Lillienau J, Hofmann AF, Barrett KE,. Activation of mast cells by bile acids. Gastroenterology 1991; 101: 446-56.
175. Goldblatt J, Taylor PJ, Lipman T, et al,. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002; 122: 1235-41.
176. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ,. Fatigue in primary biliary cirrhosis. Gut 1998; 43: 705-10.
177. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J,. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000; 95: 760-7.
178. Mells GF, Pells G, Newton JL, et al,. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013; 58: 273-83.
179. Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL,. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol 2010; 53: 911-7.
180. Abbas G, Jorgensen RA, Lindor KD,. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010; 7: 313-9.
181. Bjornsson E, Simren M, Olsson R, Chapman RW,. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004; 39: 961-8.